Many myeloma treatments (CAR-T, BLENREP, other bi-specifics, etc) target BCMA, an antigen found on 80-100% of myeloma cells. The primary endpoint of the study was met. Another anti-CD38/CD3 BiTE . Data showed skin- and taste-related side effects were common, but typically rated mild. Clin Lymphoma Myeloma Leuk. Therapies already exist for ITP, which causes dangerously low platelet levels, but they have limitations. Nearly 60% had a very good partial response, meaning that their cancer was substantially reduced. The gist was that the temporary side effect was nothing if the drug works! At median follow-ups of 11.7 months (in patients who had received talquetamab at the 405-g dose level) and 4.2 months (in those who had received it at the 800-g dose level), the percentages of patients with a response were 70% (95% confidence interval [CI], 51 to 85) and 64% (95% CI, 48 to 78), respectively. Methods: In a phase 1 study, we evaluated talquetamab administered intravenously weekly or every other week (in doses from 0.5 to 180 g per kilogram of body weight) or subcutaneously weekly . Would you like email updates of new search results? Talquetamab is a BiTE binding GPRC5D and CD3. HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. The https:// ensures that you are connecting to the . Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for New medicine for multiple myeloma patients with limited treatment Patients would describe this as everything tasting like cardboard or sawdust, or that things that they used to enjoy now tasted completely different.. This is the new unmet need in multiple myeloma.. Few side effects, though. Nurses should encourage patients to incorporate thin liquids into their diet. I hadn't realized it, but was thinking I had just lost track of when I was getting it. "It seems the total effect is a real drying effect. runny or stuffy nose. Nurses Call for More Research on Nutrition Challenges for Patients With AML/MDS. Were looking at all of that, to try to figure out how to optimize the combination of these drugs in a highly effective regimen, said Tendler. Immunotherapy is a type of treatment that affects a person's immune system. Learn more here. Get the free daily newsletter read by industry experts. We're not used to seeing that, but something important to keep in mind. New Cancer Drug Achieves 73% Response Rate in Patients Testing of that drug, known as lovo-cel, has already been stalled twice by the Food and Drug Administration due to safety concerns, causing Bluebird to fall behind a rival gene editing treatment from Vertex Pharmaceuticals and CRISPR Therapeutics thats now under rolling regulatory review in the U.S. Vertex and CRISPR aim to complete their filing by the end of the first quarter. Known in full as G protein-coupled receptor, family C, group 5, member D, the protein found on cancerous plasma cells drew attention over the weekend as Johnson & Johnson unveiled new data for an experimental multiple myeloma treatment. The results of the phase 1 trial appeared in the New England Journal of Medicine, and the phase 2 trial results were presented at the annual meeting of the American Society of Hematology. Taltz contains the active substance ixekizumab. Grade ranged from grade 1 to grade 3 for the dermatologic events. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. Epub 2022 Jun 5. I lost a lot of sleep over this, Aronson shared, noting that her patients were distressed by these AEs. In addition to various side effects including Cytokine Release Syndrome (SRS) which are seen in many targeted therapies, Talquetamab causes some "skin related and nail disorder adverse events in 75% of patients" All of the noted side effects, however, were considered manageable and reversible. These trials could give people with myeloma the chance to live longer by keeping their cancer at bay.. Dr. Chari explained: A complete response isnt actually a cure but its basically getting it down to a level where its undetectable. At the two subcutaneous doses recommended for a phase 2 study (405 g per kilogram weekly [30 patients] and 800 g per kilogram every other week [44 patients]), common adverse events were cytokine release syndrome (in 77% and 80% of the patients, respectively), skin-related events (in 67% and 70%), and dysgeusia (in 63% and 57%); all but one cytokine release syndrome event were of grade 1 or 2. N Engl J Med. Antibody Treatment Makes Inroads Against Multiple Myeloma New data from an ongoing Phase 1/2 clinical trial has revealed an experimental immunotherapy led to successful response rates in 73% of patients suffering from multiple myeloma, a deadly form of blood cancer. The years biggest meeting on blood diseases kicked off this past weekend. Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A, Chaulagain C, Raza S, Samaras C, Valent J, Khouri J, Anwer F. Cancers (Basel). Epub 2021 Aug 10. Read on for details and takeaways from the meeting over the weekend: Like many new drug targets, its name is complicated and better off abbreviated. Talquetamab is under investigation in clinical trial NCT04634552 (A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma). Bluebird attributed both to underlying genetics specifically, a condition known as alpha thalassemia trait that is associated with anemia. Dr. Ajai Chari, director of clinical research in the Multiple Myeloma Program at The Tisch Cancer Institute and lead author of both studies, explained for Medical News Today how it works: Basically one side is binding to the immune cells known as T cells, and the other side is binding to the myeloma cancer cell, and when those T cells are brought into proximity of the cancer [] they release chemicals that poke holes in the cancer cell membrane and the cancer cells die., Dr. Baker was cautiously optimistic about the therapy: Talquetamab sticks to both cancer-killing immune cells and myeloma cells, helping the immune system to recognize and destroy the cancer. The researchers said very few patients (5 to 6 percent) stopped talquetamab treatment because of side effects. 2023 Mar 18;15(6):1839. doi: 10.3390/cancers15061839. 2023 Apr;29(3):722-726. doi: 10.1177/10781552231154809. In total 70% of patients experienced Cytokine Release Syndrome (CRS) but all events were minor. Ac., CYT, Enzalutamide, combined with standard treatment, shows promise in prostate cancer, What to know about endometrial stromal sarcoma. lower back or side pain. Find out how likely it is to occur and why it happens. . Over the course of the trial, 73% of patients responded positively to the drug. Cancers (Basel). Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that redirects T-cell killing to multiple myeloma cells by binding to the novel target, GPRC5D, and CD3. Anything less doesnt count.. FOIA It is produced on the base of DuoBody technology. Here are three storylines to emerge so far. In a separate cohort, 51 patients who had previously received therapies that redirect T cells showed a response to talquetamab. and transmitted securely. Following treatment with the immunotherapy drug in the Mount Sinai Health System trial, almost three-quarters of the participants showed improvement, with 30% having a complete response to the drug. And responses tended to deepen over time. "Hydrate, hydrate, hydrate," she said. CB-011, which received fast track designation from the FDA, is currently under investigation as a treatment for those with relapsed or refractory multiple myeloma in the phase 1 CaMMouflage trial. That data has revealed most patients treated with talquetamab experienced mild side effects, but only around five percent had to cease treatment due to those adverse effects. In her role, Aronson cares for patients enrolled in the phase 1 MonumenTAL-1 trial (NCT03399799), a dose-escalation/dose-expansions study seeking to characterize the safety profile and recommended phase 2 dose for talquetamab in patients with multiple myeloma who either have relapsed/refractory disease or are ineligible for other available treatment options.2. They were divided into two groups, one of which received the drug intravenously, and the other subcutaneously. Shares climbed about 3% on Monday and, at about $400 apiece, trade near record highs. All rights reserved. Although all oral symptoms were categorized as grade 1 or 2, they still had a significant effect on quality of life and treatment continuation; dysgeusia was responsible for 3 cases of dose interruptions, 1 case of dose reduction, and 1 treatment discontinuation; dysphagia was the catalyst for 3 cases of treatment interruptions. These are patients whove had typically five lines of therapy over several years. The researchers said very few patients (5 to 6 percent) stopped talquetamab treatment because of side effects. MNT is the registered trade mark of Healthline Media. Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody that targets GPRC5D. Bluebird believes lovo-cel may exacerbate the problems linked to alpha thalassemia trait. Talquetamab for Multiple Myeloma Talquetamab, a bifunctional antibody, directs activated T cells to tumor. Anemia, in this context, can be worrisome as a potential sign of emerging blood cancer. About three-quarters of patients experienced cytokine-release syndrome, 60% experienced skin-related side effects such as rash, about half reported taste changes, and about half reported nail disorders. Talquetamab: New drug may offer hope for those with hard-to-treat blood CRS and cytopenia were primarily observed in early cycles and were reversable. One of the things that I think is very telling with efgartigimod is, no matter what subgroup we looked at, it showed a benefit over placebo, said Broome. a condition causing fever, vomiting, shortness of breath, headache and low blood . The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). A low blood cell count, called cytopenia, was among the most common adverse events . Rich has written for a number of online and print publications over the last decade while also acting as film critic for several radio broadcasters and podcasts. Moreover, with proper education regarding treatment-emergent adverse event (TEAE) management, nurses can play a critical role in improving quality of life for patients receiving talquetamab.1, Nursing education, support, and management is absolutely vital, Aronson said in a presentation on the agents AE profile during the International Myeloma Societys 6th Annual Nursing Symposium. making it an attractive therapeutic target. Generic Name. They can have a limited impact on quality of life measures.. A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. The site is secure. We have lot of patients start a nail hardener at the onset of therapy.. Ongoing trials are assessing the optimal phase 2 dose, as well as assessing the agents efficacy in combination with approved and investigational therapy. Many of those with a very good partial response had a 90% improvement., He told MNT that phase 3 trials are now underway using a the 2-weekly dosing pattern. 2023 Mar 17;15(6):1819. doi: 10.3390/cancers15061819. Oyster mushrooms contain antioxidants, which may lower cancer risk. Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Lancet. The abnormal plasma cells are made from stem cells in the bone marrow. No modifications were caused by dry mouth. Talquetamab uses a different target called GPRC5D. The median time to onset was 26.5, 6.7, and 41.5 days, respectively. Serious side effects were reported in 8% of efgartigimod-treated patients and nearly 16% of those who received placebo, but none were deemed to be drug-related. Recent advances in the treatment of multiple myeloma One year later, data presented at ASH could help the company make the case for approval in another uncommon autoimmune disease: primary immune thrombocytopenia, or ITP. Talquetamab/Daratumumab Shows Promise in Heavily Pretreated Myeloma Healthy plasma cells produce antibodies to help people fight disease. And it is also important to note that different doses were tested, and the appropriate dose was selected. The study enrolled a total of 288 patients who were unable to tolerate existing therapies or who experienced disease progression after at least three multiple myeloma therapies. In the last week of the first cycle, I checked my plasmocytoma on Saturday and it seemed a little smaller. Whats really great is that some myeloma cells NOT having BCMA MIGHT have GPRC5D. For patients experiencing palmar/plantar desquamation, ammonium lactate lotion, and emollients have shown efficacy. Children and Cancer . All participants had received at least three prior treatments, including other types of drugs. When patients are having taste changes, and their wife is in tears saying I want him to eat, he wont eat, what do I do? Thats where we really can come in and help., Aronson is a clinical nurse practitioner specializing in bone marrow transplant and immune effector cell therapies at Mount Sinai Hospital. It seems the total effect is a real drying effect. 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160. Expand Now, talquetamab, or talq for short, is a bi-specific antibody against a target called GPRC5D.